Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors. (HLX07Ib/II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03577704
Recruitment Status : Recruiting
First Posted : July 4, 2018
Last Update Posted : September 3, 2018
Sponsor:
Information provided by (Responsible Party):
Shanghai Henlius Biotech

Brief Summary:
HLX07 is a new anti-EGFR monoclonal antibody (mAb) with improved glycosylation pattern.In pre-clinical efficacy studies, HLX-07 is either equivalent or more potent than cetuximab in multiple cancer models without increased toxicities.This study is an open-labeled, dose-escalation study designed to explore the maximum tolerated dose (MTD) and safety of HLX07 in combination with different chemotherapy regimens.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Drug: HLX07+Gemcitabine+Cisplatin Drug: HLX07+Paclitaxel+Carboplatin Drug: HLX07+mFOLFOX6 Phase 1 Phase 2

Detailed Description:

This study is a parallel 3-arm escalation trial with 3 doses of HLX07 (400 mg, 600 mg, or 800 mg per single dose) combined with 3 different fixed-dose chemotherapy regimens.

Three chemotherapy regimens are:

① Gemcitabine (1000 mg/m2) and Cisplatin (75 mg/m2) , every three weeks. Gemcitabine was administered on the first day and on the 8th day, and cisplatin 75 mg/m2 was administered on the first day , a total of 4-6 cycles。

② Paclitaxel (80 mg/m2) and carboplatin (AUC=2), every 3 weeks. Paclitaxel and carboplatin were administered on days 1, 8 and 15 for a total of 4-6 cycles.

③ mFOLFOX6 protocol: oxaliplatin (85 mg/m2), leucovorin (400 mg/m2), and 5-fluouracil (5-FU) (400 mg/m2, followed by 2400 mg/m2), every 2 weeks. Oxaliplatin, leucovorin and 5-FU were administered on the first day.

After 4 to 6 cycles of (gemcitabine and cisplatin regimens) and (the paclitaxel and carboplatin regimens) or after 6 to 12 cycles of the mFOLFOX6 regimen, well-controlled patients will be continue to receive a weekly HLX07 infusion as maintenance therapy for maximum 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).

The study used the Bayes optimal interval design (BOIN) to determine the MTD of HLX07 in combination with chemotherapy.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: The study used the Bayes optimal interval design (BOIN) to assign the subject's dose level and determine the maximum tolerated dose (MTD) of HLX07 in combination with chemotherapy.Each cohort contains 3 subjects and the patient in the first cohort receives treatment at the lowest dose level (single dose of 400 mg). The decision to increase or decrease the dose after each train is based on the probability of a predefined safety and toxicity threshold. When the observed rate of dose limiting toxicity (DLT) is less than 0.237 (low target safety margin), the dose for the next cohort escalates; when the observed rate of DLT is higher than 0.359 (target high toxicity cutoff), the dose deescalates. Otherwise, the dose remains the same. After each cohort is finished, a safety review committee will be held to determine the escalates or deescalates in the next cohort. The enrollment continues until the maximum 30 patients are reached.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Exploratory Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of HLX07 (Recombinant Anti-EGFR Humanized Monoclonal Antibody) Combined With Chemotherapy in Patients With Advanced Solid Tumors.
Actual Study Start Date : August 8, 2018
Estimated Primary Completion Date : September 30, 2021
Estimated Study Completion Date : October 30, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: HLX07+Gemcitabine+Cisplatin arm

HLX07 is given on D1,D8,D15 combine with Gemcitabine (1000 mg/m2) and Cisplatin (75 mg/m2) in 3 weeks- cycles for 4-6 cycles .Gemcitabine was administered on the D1 and D8 and cisplatin 75 mg/m2 was administered on the D1. After 4-6 cycles of combination therapy, once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).

In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD.

Drug: HLX07+Gemcitabine+Cisplatin

Recombinant anti-EGFR humanized monoclonal antibody in combination with Gemcitabine and Cisplatin.

HLX07, IV, weekly.

Other Names:
  • Recombinant anti-EGFR humanized monoclonal antibody
  • Gemzar
  • Cisplatin

Experimental: HLX07+Paclitaxel+Carboplatin arm

HLX07 is given on D1,D8,D15 combine with Paclitaxel (80 mg/m2) and carboplatin (AUC=2) in 3 weeks-cycle for 4-6 cycles .Paclitaxel and carboplatin were administered on D1, D8 and D15. After 4-6 cycles of combination therapy, once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).

In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD.

Drug: HLX07+Paclitaxel+Carboplatin

Recombinant anti-EGFR humanized monoclonal antibody in combination with Paclitaxel and Carboplatin.

HLX07, IV, weekly.

Other Names:
  • Recombinant anti-EGFR humanized monoclonal antibody
  • Paclitaxel
  • Carboplatin

Experimental: HLX07+mFOLFOX6 arm

HLX07 is given on D1,D8 combine with mFOLFOX6 ( oxaliplatin (85 mg/m2), leucovorin (400 mg/m2), and 5-FU (400 mg/m2, followed by 2400 mg/m2) in 2 weeks-cycles for 6-12 cycles . Oxaliplatin, leucovorin and 5-FU were administered on D1. After 6-12 cycles of combination therapy,once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).

In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD.

Drug: HLX07+mFOLFOX6

Recombinant anti-EGFR humanized monoclonal antibody in combination with Oxaliplatin, Calcium Folinate and 5-FU.

HLX07, IV, weekly.

Other Names:
  • Recombinant anti-EGFR humanized monoclonal antibody
  • Oxaliplatin for Injection
  • Folinic acid calcium salt hydrate
  • 5-fluouracil




Primary Outcome Measures :
  1. The maximum tolerated dose of HLX07 combined with different chemotherapy regimen [ Time Frame: up to 24 months ]
    The incidence of DLT combined with different chemotherapy regimens based on NCI CTCAE v4.03



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with histologically confirmed metastatic or recurrent advanced solid tumors which has indication to receive treatment with one of above three chemotherapy regimens.The lesions must be assessable based on the RECIST v1.1 criteria.The number of previously received chemotherapy regimens should not exceed two.
  2. At least 28 days from prior major surgery, prior cytotoxic chemotherapy, or prior therapy with investigational agents or local radiotherapy and at least 42 days from the last infusion of immune check point inhibitors (The antibodies or drugs include but not limited to IDO, PD-1, PD-L1, IL-2R, CTLA-4, CD137, and GITR) before the first infusion of investigational product.
  3. Eastern Cooperative Oncology Group (ECOG) score ≤ 1,
  4. Expected survival time ≥ 3 months;
  5. Has sufficient hematological function, defined as: neutrophil absolute value ≥ 1.5 × 109 / L; hemoglobin level ≥ 9.0 g / dL ; Platelet count ≥100×109 /L.
  6. Has sufficient liver function, defined as: total bilirubin level ≤ 1.5 × upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤ 2.5 × ULN, For patients with known liver metastases or primary hepatocellular carcinoma patients ≤ 5 x ULN.
  7. Has adequate coagulation function defined as: International normalized ratio (INR) ≤ 1.5 or prothrombin time (PT) ≤ 1.5 x ULN, and activated partial thromboplastin time (PTT) in the absence of anticoagulant therapy /aPTT) ≤ 1.5 x ULN.
  8. Has adequate cardiac function, defined as: left ventricular ejection fraction (LVEF) ≥ 50%.
  9. Has sufficient renal function; in patients receiving the gemcitabine plus cisplatin regimen is defined as creatinine clearance ≥ 60 ml/min and in patients receiving the paclitaxel plus carboplatin regimen or the mFOLFOX6 regimen, is defined as creatinine clearance ≥ 50 ml/min (calculated by the Cockcroft-Gault formula).
  10. Use of effective contraceptive measures if procreative potential exists.
  11. Able to provide written informed consent.

Exclusion Criteria:

  1. Concurrent unstable or uncontrolled medical conditions. Either of the followings:

    • Active systemic infections;
    • Poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥100 mmHg), or poor compliance with anti-hypertensive agents;
    • Clinically significant arrhythmia, unstable angina pectoris, congestive heart failure (class III or IV of New York Heart Association (NYHA)) or acute myocardial infarction within 6 months;
    • Uncontrolled diabetes or poor compliance with hypoglycemic agents;
    • The presence of chronically unhealed wound or ulcers;
    • Other chronic diseases, which, in the opinion of the investigator, could compromise safety of the patient or the integrity of study.
  2. Unstable central nervous system (CNS) metastasis. Patients who have previously undergone surgery or radiotherapy for brain metastases may participate in this study if they are clinically stable for at least 4 weeks and has stopped steroids for at least 2 weeks prior to the first infusion of the test drug and there is no new evidence of progression.
  3. Has primary central nervous system malignancy;
  4. Known patients have drug allergies to specific drug regimens (eg anti-EGFR monoclonal antibodies, gemcitabine, platinum, paclitaxel, fluorouracil allergy);
  5. known active hepatitis B or C infection (active hepatitis B is defined as hepatitis B surface antigen HBsAg positive and Hepatitis B virus (HBV) DNA> 500 copies / ml; active hepatitis C is defined as hepatitis C antibody-positive and / or quantitative Hepatitis C virus (HCV) RNA results positive);
  6. Human immunodeficiency virus infection .
  7. Pregnancy or breast-feeding woman.
  8. Patients with colorectal cancer whose tumors have K-ras, N-ras, or B-raf mutations;
  9. The patient has a history of alcohol abuse or drug abuse;
  10. Use of herbal medicine within the first 2 weeks before the first infusion of the test drug;
  11. Treatment with systemic steroids (equivalent to >10 mg/day of methylprednisolone) or any other form of immunosuppressive therapy within 2 weeks of the first infusion of the test drug;
  12. Patient has a history or current evidence of any condition or disease that could confound the results of the study, or is not the best interest of the patient to participate, in the opinion of Investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03577704


Contacts
Layout table for location contacts
Contact: Siwei Bao, MS +86 21 38804518 ext 22198 siwei_bao@163.com

Locations
Layout table for location information
China, Shanghai
Shanghai East Hospital Recruiting
Shanghai, Shanghai, China, 200123
Contact: Jin E Li, Phd    (021)38804518 ext 22228    lijin@csco.org.cn   
Contact: Jin E Li       lijin@csco.org.cn   
Principal Investigator: Jin Li, PhD         
Sub-Investigator: Ye Guo, PhD         
Sponsors and Collaborators
Shanghai Henlius Biotech
Investigators
Layout table for investigator information
Principal Investigator: Jin E Li, PhD No.1800 Yuntai Road,Pudong District,Shanghai

Layout table for additonal information
Responsible Party: Shanghai Henlius Biotech
ClinicalTrials.gov Identifier: NCT03577704     History of Changes
Other Study ID Numbers: HLX07-002
First Posted: July 4, 2018    Key Record Dates
Last Update Posted: September 3, 2018
Last Verified: August 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Paclitaxel
Albumin-Bound Paclitaxel
Cisplatin
Gemcitabine
Carboplatin
Oxaliplatin
Antibodies
Immunoglobulins
Antibodies, Monoclonal
Calcium
Antineoplastic Agents, Immunological
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antimetabolites
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcium-Regulating Hormones and Agents